Gemme: Accueil

EGA vision
The European Generic medicines Association (EGA) is at the heart of Europe’s
medicines industry and is essential to EU Public Health
• Patients
1
2
3
4
5
D Patient access to medicines significantly increases
D
when generic medicines companies enter the market
52% of all medicines taken by patients in Europe are generic medicines
• Quality
D Generic medicines are developed according to stringent regulatory
requirements. Manufacturing is also highly regulated
D We advocate the enforcement of the highest quality standards in all
countries around the world – as you would find in the EU
• Value
D Average daily cost of a generic medicine is just 25 Eurocents
D Generic and biosimilar medicines save 35 bn euros per year
D This is an incredible service to patient health and budget control
D The EU 28 must stimulate the healthcare systems to use generics
• Sustainability
D 75% of generic medicines consumed are produced in the EU
D The EU has 1000 companies with 150,000 employees
D Generic medicines companies are innovating: 7% R&D investment
D We must support this industry to grow and lead in the world through
allowing manufacture for export during EU SPC
• Partnership
EGA | EUROPEAN GENERIC MEDICINES ASSOCIATION
Rue d’Arlon 50 B-1000 Brussels | Belgium
T: +32 (0) 2 736 84 11 | F: +32 (0) 2 736 74 38
www.egagenerics.com | [email protected]
D The European Generic medicines Association (EGA) will work in close
collaboration with the EU Institutions, governments, patients groups,
healthcare professional groups and other stakeholders to enhance EU
public health
The EGA is the official representative body of the European generic and biosimilar medicines industry, which is at the forefront of providing high-quality
affordable medicines to millions of Europeans and stimulating competitiveness
and innovation in the pharmaceutical sector.